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Summary The effects of butyrate and retinoic acid in combination with catecholamines or histamine on the
HN-1 human head and neck squamous carcinoma cell line were investigated analysing cell proliferation,
placental alkaline phosphatase (PLAP) activity, and relative cytokeratin content.
Butyrate inhibited cell proliferation in agar, whereas retinoic acid induced a small inhibitory effect. Butyrate
enhanced PLAP activity in a time related manner in contrast to retinoic acid, which had no significant effect.
However, retinoic acid inhibited the efficacy of butyrate to induce PLAP activity. A synergistic enhancement
of PLAP activity was demonstrated after treatment of butyrate pretreated cells with catecholamines or
histamine. The f,-adrenergic antagonist propranolol partly inhibited the aforementioned enhancement of PLAP
activity, whereas the x-adrenergic antagonist phentolamine further enhanced PLAP activity. Indirect labeling
of keratins with a polyclonal antibody showed that cytokeratin content was enhanced by butyrate but not by
retinoic acid. Further analysis of cytokeratin content using four monoclonal antibodies showed that labeling
of cytokeratins (5+8) was increased by butyrate.
PLAP activity could be modulated by a concerted action of either butyrate plus retinoic acid or butyrate
plus catecholamines or histamine, indicating a possible role for PLAP in tumour cell proliferation.
Squamous cell carcinomas of the head and neck region often
contain large keratinized patches of well differentiated
squamous cells embedded in nests of less differentiated
tumour cells. The malignant stem cell compartment in the
tumour presumably gives rise to a progeny of cells that
either continues to proliferate or acquires differentiation
characteristics which finally gives rise to terminally matured
end-stage cells.
As is shown in numerous reports, butyrate, retinoic acid,
interferon, glucocorticoids, polar solvents, and certain chemo-
therapeutic agents can modulate terminal differentiation
(Augeron & Laboisse, 1984; Burke, 1986; Jetten, 1984; Reiss
et al., 1985; Sartorelli, 1985), accompanied by inhibition of
proliferation (Pierce & Wallace, 1971; Prasad & Sinha,
1976), morphological changes (Abe & Kufe, 1984; Kamech
et al., 1986), and an increase in the production of specific
antigens and enzymes (Reese & Politano, 1981; Morita et al.,
1982; Abe & Kufe, 1984; Reese et al., 1985), such as CEA
and alkaline phosphatase. These effects were in most cases
reversible, although some authors claimed a more
permanently affected cell progeny after treatment (Augeron
& Laboisse, 1984; Reiss et al., 1985). It was indicated that
for example butyrate and retinoic acid provided a trigger
mechanism, which if properly administered to a cell would
eventually lead to a terminally matured tumour cell.
Recently it was shown that cAMP-elevating agents like
catecholamines, potentiated the action of retinoic acid in
eliciting normal epithelial cell differentiation (Schiff &
Moore, 1985). Catecholamines have other intriguing effects
on cells, including regulation of cell division (Kennedy et al.,
1985; Tutton & Barkla, 1980), induction of alkaline
phosphatase (Mary & Rao, 1981), and reduction of the total
number of EGF receptors (Cruise et al., 1986). In the light
of the increased number of EGF receptors on malignant
squamous cells the aforementioned effect might be very
promising (Cowley et al., 1986).
The present study, using HN-1 squamous carcinoma cells,
demonstrated that butyrate inhibited clonogenicity in soft
agar, enhanced placental alkaline phosphatase (PLAP)
activity, and increased relative cytokeratin content, in
contrast to retinoic acid. Retinoic acid, however, inhibited
the enhancement of PLAP activity induced by butyrate.
Receptor studies with HN-1 cells showed that fl-adrenergic-
like receptors were present (Bijman et al., 1987). In view of
the diverse effects of catecholamines on tumour cells,
combinations with butyrate or retinoic acid were examined.
Materials and methods
Chemicals
Drugs used were (±)epinephrine, (±)norepinephrine,
(±)isoproterenol, dopamine, histamine, (±)propranolol,
cimetidine, phentolamine (Ciba Geigy), sodium butyrate,
and all-trans-retinoic acid. For enzyme analysis 4-methyl-
umbelliferyl phosphate (4-MUP), 4-methylumbelliferyl (4-
MU), and 2-amino-2-methyl-1, 3-propanediol were used. The
4-MUP was purified before use to remove traces of free 4-
MU. For DNA analysis 4',6-diamidino-2-phenylindole
(DAPI, Boehringer) was used. All chemicals without
company name acknowledged in parentheses were from
Sigma.
Cell culture
An established cell line, designated HN-1, was used for the
present experiments. The cell line was derived from a human
squamous cell carcinoma of the tongue (Easty et al., 1981)
and was kindly made available by Dr G. Haemmerli of the
Division of Cancer Research, University of Zurich,
Switzerland.
Cells were routinely grown in 25 cm2 culture flasks
(Costar) using Eagle's minimal essential medium (MEM;
Gibco Europe) supplemented with 10% foetal bovine serum
(FBS; Gibco Europe) plus 50,ugml - gentamicin
(Boehringer) and 2 mM L-glutamine (Gibco Europe). Cells
were stored at 37°C in a humidified atmosphere (Heraeus,
B-5060 EC/02) in a gas phase of 5% COV 10% 02' and
85% N2.
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Colonyformation in semi solid medium
For clonogenicity tests, 5,000 cells were cultured in 35mm
culture dishes (Costar) in 1 ml 0.3% soft agar (Bacto Difco)
made with a medium mixture (1:1) of conditioned medium
from routine HN-1 cultures (7 days in culture) and MEM
plus 10% FBS. The underlayer (1 ml) was 0.5% agar in
MEM plus 10% FBS. The stock agar solution (3%) was
always boiled (15 min) immediately before use without
prior autoclaving, was made fresh for each experiment, and
was kept in a water bath at 50°C.
Cells were cultured with various concentrations of
butyrate or retinoic acid continuously present, or after a 3-
day pretreatment. After a 14 day incubation period colonies
were counted with an inverted phase contrast microscope
(Olympus, CK2-Tr). Plating efficiency of control HN-1
cultures was generally 10%.
Flow cytometry
Exponentially growing HN-1 cells (3 days) were made
quiescent by serum deprivation for 3 days in 0.25% FBS.
Subsequently, the cells were released from growth arrest by
adding the conditioned medium obtained from the first 3
days in culture plus additive (butyrate or retinoic acid). Cell
proliferation was monitored for 48h taking samples at 12h
intervals. Cells were trypsinized and fixed in cold ethanol
(70%). DNA and protein content were determined by flow
cytometry. Flow cytometric analyses were performed as
previously described (Bijman et al., 1985). Aliquots of
106 ml-1 ethanol fixed cells were stained in PBS plus
1 mM EDTA containing 15jugml -1 propidium iodide
(Calbiochem), 0.02 igml -1 fluorescein isothiocyanate
(FITC), and 0.1 mgml -1 RNAse (Sigma). Dual-parameter
measurements (64 x 64 channels) were obtained by
comparing relative DNA (red) vs. relative protein (green)
content.
For cytokeratin analysis ethanol fixed cells were labeled
(30 min) with K-40, which is a broadly cross-reacting
polyclonal antibody for cytokeratins as described elsewhere
(Ramaekers et al., 1984; Bijman et al., 1986) or with 4
different monoclonal antibodies i.e., RCK-102, RCK-105,
RKSE-60, and RCK-106, analysing cytokeratins 5+8, 7, 10,
and 18 respectively (Ramaekers et al., 1983). For classification
see Moll et al. (1982). Cells were washed 3 times with PBS
plus 5% FBS and subsequently labeled with a FITC-
conjugated second antibody. Cells were washed 3 times and
stained with propidium iodide (15jygml-1), to perform two-
colour (green vs. red) fluorescence measurements. The data
accumulated were directly stored on hard disc using a
Digital PDP-1 I computer. Generally 30,000 cells were
analysed for each measurement.
Biochemical analysis
From stationary growth phase cultures (7 days in culture)
105 cells were subcultured in 25cm2 flasks in 4ml MEM plus
10% FBS. After a 4 day exponential growth period, cells
were treated with either butyrate (2mM) or retinoic acid
(10-9M). Catecholamines, histamine, and antagonists were
added to the medium 24h after the start of butyrate or
retinoic acid treatment, without changing the medium. Cells
were trypsinized, centrifuged in MEM plus 10% FBS (5 min,
200g), and resuspended in 1 mgml- bovine serum albumin
(BSA) in water. All specimens were stored for up to 3 days
at -80°C. Cells were lysed using one cycle of freeze-thawing
followed by sonication (10 sec-twice; amplitude of 12
micron; Soniprep 150, MSE). Suspensions were incubated at
62°C overnight in a water bath (17h) to inactivate all non-
placental isoenzymes and centrifuged for Smin at 2000g.
Placental alkaline phosphatase (PLAP) activity was
determined as described elsewhere (Mier & Rennes, 1982a).
Briefly, the PLAP reagent contained final concentrations of
0.5mM 4-MUP (diluted from purified stock solution),
5mMNaF, and 100mM 2-amino-2-methyl-1, 3-propanediol
at pH 9.8. The reaction was initiated by the addition of
204u1 reagent to 400 u1 sample. After an incubation period
of I h at 37°C, the tubes were transferred to ice and I ml
carbonate-bicarbonate buffer (200mM, pH 10.5) was added.
Fluorescence was measured at Aex=372nm and Aem =
438 nm (Aminco, Bowman). After subtraction of the blank,
the 4-MU liberated was calculated using a reference standard
of I gM 4-MU in carbonate-bicarbonate buffer.
DNA content of the specimens was determined as the
fluorescent complex with DAPI by adding 50p1 of a
20ngml-l DAPI solution in 10mM Tris/HCl with ph7.0
(Mier & Rennes, 1982b). Fluorescence was measured at Rex =
372 nm and )em=438 nm. DNA from calf thymus was
used as standard (400 gml-1 in 5ml NaOH). All assays
were carried out in duplicate and appropriate controls were
included. PLAP activity was expressed as pmol 4-MU
released min 1 g 1 DNA.
Results
Effect ofbutyrate and retinoic acid on proliferation
The effect of butyrate (0.5-2.5mM) and retinoic acid (101
10-7 M) on the proliferation of HN-1 cells was monitored
after a 3 day pretreatment of cells in the exponential growth
phase or treatment during colony growth in soft agar.
Butyrate inhibited colony growth of HN-1 cells in a dose-
dependent manner, when continuously present. Complete
inhibition of colony growth occurred at 2.5mM butyrate
(Figure IA). Pretreatment with various concentrations of
butyrate for 3 days and subsequent culture produced a
minor inhibition. In contrast retinoic acid when continuously
present exhibited a small inhibitory effect on colony growth.
However, pretreatment for 3 days with various concen-
trations of retinoic acid increased clonogenicity (Figure 1B).
The average size of the colonies increased (data not shown)
compared to controls.
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Figure I The effect of a 14 day (continuous) incubation or a 3
day pretreatment with butyrate (A) or retinoic acid (B) on the in
vitro response of HN-1 cells grown in 0.3% soft agar. (A),
Continuous incubation; (0), 3 day pretreatment. Clonogenicity
data expressed as % of control (mean of two separate
experiments).
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In Figure 2 are shown flow cytometric analyses of
synchronized HN-1 cells treated for 48h with 2mM butyrate
or 10-9M retinoic acid at the time of release from growth
arrest (all cells in G1 phase). Relative DNA content was
compared with relative protein content. Retinoic acid had no
effect on the first cohort (24h) of cells entering the cell cycle.
The cells ceased proliferating after the first cycle, whereas in
control cultures (data not shown) approximately half of the
population was still in cycle. It was noted that retinoic acid
treated cells adhered more firmly to the plastic flask, when
trypsinizing the cells. In contrast butyrate clearly inhibited
the cells from entering the cell cycle, although some cells
escaped the blockade. These cells were inhibited again at the
G2M transition (48h). The number of cells in culture was
the same at both Oh and 48 h, indicating that the cells could
not finish the cell cycle.
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Figure 2 Representative flow cytometric dual-parameter
measurements (64 x 64 channels) of HN-l cells stained with
propidium iodide for DNA content (abscissa) and with FITC for
protein content (ordinate). Cells were released from a forced
stationary phase (in 0.25% FBS), treated with 10-9 M retinoic
acid or 2 mm butyrate, and monitored at 12h intervals of which
the 24h, 36h, and 48 h data are shown. For each dual-parameter
measurement 30,000 cells were processed.
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Figure 3 Time related response of PLAP activity in HN-1 cells
to butyrate (2mM) and retinoic acid (0-9M). (-)? control; (A),
2mm butyrate; (-), 10-9M retinoic acid. Points, mean of four
separate experiments +s.d.
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Figure 4 Effect of retinoic acid on the efficacy of butyrate to
enhance PLAP activity. Pretreatment (24h) with 2 mM butyrate
(A) or 10-8 M retinoic acid (U) followed by a combined
treatment with the indicated concentrations of retinoic acid or
butyrate for 48 h. PLAP activity in butyrate (A) or retinoic acid
(M) treated cells (72h) is used as control. Points, mean ratio of
three separate experiments+s.d.
Pretreatment with 2mM butyrate for 24h followed by an
additional 48 h combined incubation with retinoic acid
(10-10-10-6 M) clearly showed that even during butyrate
treatment retinoic acid inhibited PLAP.
Effects ofbutyrate and retinoic acid on PLAP activity
Exponentially growing HN- 1 cells (4 days =day 0) had a
PLAP activity of 2.22+0.69 pmol min - jIg- DNA. After 7
days (day 3) the activity was enhanced two-fold. As shown
in Figure 3, 2mM butyrate induced a significant time related
activation of PLAP. After 72 h the PLAP activity was
enhanced approximately 10-fold compared to untreated cells.
Retinoic acid (10-9 M) had a small but insignificant effect on
PLAP activity.
Figure 4 shows that pretreatment of exponentially growing
HN-1 cells with 10-8M retinoic acid for 24h inhibited the
stimulatory effect on PLAP activity of a subsequent 48 h
combined incubation with butyrate (0.5-2.5 mM).
The effect ofcatecholamines and histamine on PLAP activity
Catecholamine and histamine receptor involvement was
investigated using several ligands. As shown in Figure 5
epinephrine, norepinephrine, and dopamine had no effect on
PLAP activity, whereas isoproterenol and histamine
produced a small activation of PLAP compared to untreated
cells. A 24h pretreatment with 2mM butyrate, followed by a
combined treatment for 24h with one of the catecholamines
or histamine produced a synergistic enhancement of PLAP
activity compared to PLAP activity in butyrate treated (48h)
cells. Pretreatment with 10-9M retinoic acid followed by a
combined treatment with catecholamines or histamine had
no effect on PLAP activity compared to the PLAP activity
in retinoic acid treated cells.
< 35-
z
0
730-
c 25-
o& 20-
>. 15
0 X 10
-X 0L5
* X w
I I I
........:
........
;,..
...
....... ..130 J.Th. BIJMAN et al.
Isoprotereno MONo000/////////////////7//7//M
Epinephrine
Norepinephrine
Dopamine
Histamine
10.
I . . 1
1 5
Relative PLAP activity
The effect ofbutyrate and retinoic acid on cytokeratins
Figure 7A shows a flow cytometric analysis iof relative
cytokeratin content and relative DNA content of cells
exponentially growing for 4 days. In Figure 7B, C are
documented the effects of 10-9 M retinoic acid and 2mM
butyrate treatment (48h) on relative keratin content
respectively. Butyrate (Figure 7C) clearly enhanced the
relative keratin content, whereas retinoic acid exerted no
effect. The data on retinoic acid treated cells (Figure 7B) are
comparable with those obtained with control cultures (48h).
Further investigations using 4 monoclonal antibodies with
which cytokeratins 5+8, 7, 10, and 18 can be distinguished,
showed that butyrate increased labeling of cytokeratins 5+8
(Table I), whereas with retinoic acid again no effect was
detectable.
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Figure 5 Effect of 10- 5 M catecholamines or histamine on
PLAP activity. (El), without pretreatment; PLAP activity in
untreated cells is used as control. (f3), pretreatment (24h) with
2mM butyrate, followed by a 24h combined treatment of
butyrate with the indicated amine; PLAP activity in 2mM
butyrate treated cells (48h) is used as control. (-), pretreatment
(24h) with 10-9M retinoic acid, followed by a 24h combined
treatment of retinoic acid with the indicated amine; PLAP
activity in retinoic acid treated cells (48h) is used as control.
Ratio is average of 2 separate experiments.
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The effect ofantagonists on PLAP activity
Dose response curves of the antagonists propranolol and
phentolamine on PLAP activity are shown in Figure 6.
Pretreatment of cells with 2mM butyrate (24h) followed by a
combined treatment (24h) of butyrate with 10 M
isoproterenol plus the indicated concentrations of
propranolol produced a partial inhibition of PLAP activity.
In contrast, phentolamine produced an enhancement of
PLAP activity compared to control cells treated with
norepinephrine plus butyrate. Cimetidine (H2 antagonist)
had no effect on PLAP activity induced by histamine plus
butyrate (data not shown).
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Figure 7 Representative flow cytometric dual-parameter
measurements (64 x 64 channels) of HN-1 cells stained with
propidium iodide (ordinate) and FITC-indirect immuno-
fluorescence of cytokeratin (abscissa). (A), control culture
exponentially growing at day 4; (B), cells treated at day 4 with
10 -9M retinoic acid for 48h. Control cells at day 6 gave similar
results; (C), cells treated at day 4 with 2mM butyrate for 48h.
For each dual-parameter measurement 30,000 cells were
processed.
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Figure 6 Effect of propranolol (A) or phentolamine (0) on
PLAP activity induced by butyrate plus catecholamine. Cells
were pretreated with 2mm butyrate for 24h followed by a
combined treatment of butyrate with either 10-M isoproterenol
(A) or 10- M norephinephrine (A) plus the indicated
concentrations propranolol or phentolamine. PLAP activity in
cells treated with 2mM butyrate plus isoproterenol or
norephinephrine is used as control. Points, mean ratio of three
separate experiments+s.d.
Discussion
The results of this report confirmed the observations made
by numerous investigators concerning the effect of sodium
butyrate on tumour cells (Morita et al., 1982; Augeron &
Laboisse, 1984; Reese et al., 1985). Butyrate increased or
diminished the activities of several enzymes depending on the
cell type under investigation (Prasad, 1980) or influenced the
production of certain proteins, i.e. a-foetoprotein, albumin,
or carcinoembryonic antigen (Abe & Kufe, 1984; Nakagawa
et al., 1985). These changes in gene expression were most
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Table I Effect of butyrate and retinoic acid on HN-1 keratin
filaments analyzed by flow cytometry using 4 monoclonal antibodies
RCK-102 RCK-105 RKSE-60 RCK-106
CK-(5+8) CK-7 CK-10 CK-18
Controla + b + + +
Butyrate + + + + +
(I mM)
Retinoic Acid + + + +
(10-8 M)
aamplifier gain was set with control cells using RCK-102, until a
similar multiparameter display was obtained as shown in Figure 7A;
b +' =positive staining (compare with Figure 7A); '+ +' =enhanced
staining (compare with Figure 7C); '±'=less staining than control
(compare with Figure 7B).
probably due to alterations in chromatin structure (Kitzis et
al., 1980) and the increased chromatin acetylation (Riggs et
al., 1977), which induced an increase in transcription.
In this study we have presented well documented results in
which modulation of cell proliferation, PLAP activity, and
relative keratin content have been attributed to a
responsiveness to butyrate and retinoic acid which are
believed to be strong modulators of maturation (Augeron &
Laboisse, 1984). Note the strong (Figure 4) inhibitory effect
of retinoic acid on the efficacy of butyrate to stimulate
PLAP activity. Clarification of the mechanisms of action and
the exact role of (placental) alkaline phosphatase in
proliferation would greatly improve our knowledge of
tumour cell growth. A concerted action of butyrate and
catecholamines may be mediated by complementary types of
effects at the intracellular level. The results obtained with
antagonists indicated that either receptor binding modulated
the effect of butyrate, or butyrate amplified the signals
elicited by binding to their receptors, or the cascade of
biochemical events occurring subsequent to receptor binding.
It has been reported that butyrate induced the synthesis of,B-
adrenergic receptors in HeLa cells (Tallman et al., 1977) and
their subsequent coupling to adenylate cyclase (Henneberry
et al., 1977), which greatly strengthens the latter hypothesis.
It might explain why phentholamine plus norepinephrine
induced a higher PLAP activity in butyrate treated cells.
Phentholamine inhibited a-adrenergic receptors, enabling
more binding of norepinephrine to f3-adrenergic receptors,
which were already increased in number by butyrate.
In normal human keratinocytes vitamin A exerted a
prominant effect on the type of keratin synthesized (Fuchs &
Green, 1981; Kim et al., 1984). Therefore, enhancement of
cytokeratin content (cytokeratins 5+8) induced by butyrate
and not by retinoic acid was very interesting. It is tempting
to assume that correlation of certain biochemical changes in
the cell with cessation of cell proliferation may imply dif-
ferentiation to a more mature phenotype. However, it is
pertinent to note that still many important questions
concerning links to cell maturation need to be answered
unambiguously. It indicated that the use of alternative
characterization techniques is warranted, including more
research on the type of keratin expressed (Kim et al., 1984;
Moll et al., 1982), possible detection of the precursor protein
involucrin of the cornified envelope (Reiss et al., 1985), or
analysis of possible transglutaminase activity induced by
differentiation-inducing agents (Mier et al., unpublished
results).
In conclusion, butyrate enhanced PLAP activity, which
could be inhibited by retinoic acid or synergistically enhanced
by butyrate plus catecholamines. The results obtained with
antagonists showed that the effect on PLAP activity was
exerted by stimulation of catecholamine-like receptors.
Furthermore, butyrate increased cytokeratin content of
HN-1 cells, which appeared to be due to keratins 5+8.
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